GB Sciences, Inc. (OTCQB:GBLX) is a data-driven drug development company that leverages machine learning & high-throughput biology to transform plant-inspired drug development targeting novel treatments for multi-billion-dollar biopharma markets. Our AI-Powered Drug Discovery Platform (PhAROS™) predicts novel, simple, plant-based mixtures to address unmet health needs. PhAROS™ leverages demonstrated healing from 12 global Traditional Medical Systems; pre-validates novel, simple, plant-based mixtures; and goes beyond looking at what has worked within plant-based medicines in the past to predicting the efficacies of entirely new formulations. GB Sciences’ novel AI-powered drug discovery platform has yielded 8 US & 14 global issued patents (28 unique formulas) and has 15 US and 41 global patents-pending (25 unique formulas). Gb Sciences has 5 late preclinical programs for novel treatments of Parkinson’s disease, chronic pain, stress & anxiety, cytokine syndromes, and heart failure.